|
Matthew G. Cyr, Ph.D. earned his doctoral degree from The Scripps Research Institute, where he discovered novel antibodies and cancer-specific targets under the mentorship of Dr. Christoph Rader. His work also entailed engineering novel antibodies into therapeutically relevant formats for treating cancers. Upon completion of his graduate studies in 2022, he transitioned to a Senior Scientist role at Arrowhead Pharmaceuticals, where he is currently developing novel platforms for extra-hepatic delivery of siRNA.
|
